A Phase II Study of Atezolizumab for Pretreated Advanced/recurrent Non-small Cell Lung Cancer with Idiopathic Interstitial Pneumonias: Rationale and Design for the TORG1936/AMBITIOUS Study

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2020 May 20

PMID 32426051

Citations 5

Authors

Satoshi Ikeda

Terufumi Kato

Hirotsugu Kenmotsu

Takashi Ogura

Shunichiro Iwasawa

Tae Iwasawa

Rika Kasajima

Yohei Miyagi

Toshihiro Misumi

Takeharu Yamanaka

Hiroaki Okamoto

Affiliations

Soon will be listed here.

Abstract

Background: Approximately 10% of patients with non-small cell lung cancer (NSCLC) are complicated with comorbid interstitial pneumonia (IP) with a poor prognosis. The pharmacotherapy for advanced lung cancer occasionally induces fatal acute exacerbation of pre-existing IP. Due to the lack of prospective studies, there is an urgent need to establish a safe and effective pharmacotherapy, especially for second-line or later settings. Atezolizumab, an anti-programmed cell death-ligand 1 antibody, is thought to be the safest candidate for second-line therapy among various immune checkpoint inhibitors. Moreover, compared with patients without IP, the patients with comorbid IP may have higher tumor mutation burden (TMB) or microsatellite instability (MSI), which are partly associated with a more favorable response to immune checkpoint inhibitors.

Methods: The Thoracic Oncology Research Group 1936/AMBITIOUS study is an ongoing, multicenter, single-arm, phase II trial to assess the safety and efficacy of atezolizumab for pretreated advanced/recurrent patients with NSCLC complicated with idiopathic, chronic fibrotic IP with a forced vital capacity of >70%. The patients will receive atezolizumab (1200 mg, day 1) every 3 weeks until the discontinuation criteria are met. The primary end point of this study is the 1-year survival rate, and a sample size of 38 patients is set. As a translational research, we will perform the analysis of TMB, somatic mutations, and MSI for nucleic acids extracted from archival tumor samples.

Discussion: Since there is no standard second-line or later therapy of advanced NSCLC with IP, the results of this study are expected to have a major impact on clinical practice.

Trial Registration: Japan Registry of Clinical Trials, jRCTs031190084, registered 26 August 2019 - retrospectively registered, https://jrct.niph.go.jp/en-latest-detail/jRCTs031190084.

Citing Articles

Advancing the Boundaries of Immunotherapy in Lung Adenocarcinoma with Idiopathic Pulmonary Fibrosis by a Biomimetic Proteinoid Enabling Selective Endocytosis.

Jiang A, Zheng X, Yan S, Yan J, Yao Y, He W ACS Nano. 2024; .

PMID: 38319028 PMC: 10883119. DOI: 10.1021/acsnano.3c09852.

Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.

Hu X, Wang L, Shang B, Wang J, Sun J, Liang B Front Immunol. 2023; 14:1094414.

PMID: 36949956 PMC: 10025397. DOI: 10.3389/fimmu.2023.1094414.

CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy.

Lin Q, Wu H, Song Q, Tang Y Front Oncol. 2022; 12:937277.

PMID: 36267975 PMC: 9577189. DOI: 10.3389/fonc.2022.937277.

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.

Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L Ther Adv Med Oncol. 2021; 13:1758835921992968.

PMID: 33643442 PMC: 7890731. DOI: 10.1177/1758835921992968.

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.

Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y J Thorac Oncol. 2020; 15(12):1935-1942.

PMID: 32858235 PMC: 7446731. DOI: 10.1016/j.jtho.2020.08.018.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco L . RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014; 211(5):943-59. PMC: 4010901. DOI: 10.1084/jem.20130790. View

Costabel U, Inoue Y, Richeldi L, Collard H, Tschoepe I, Stowasser S . Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med. 2015; 193(2):178-85. DOI: 10.1164/rccm.201503-0562OC. View

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2016; 389(10066):255-265. PMC: 6886121. DOI: 10.1016/S0140-6736(16)32517-X. View

Watanabe N, Niho S, Kirita K, Umemura S, Matsumoto S, Yoh K . Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol. 2015; 76(1):69-74. DOI: 10.1007/s00280-015-2775-y. View

Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K . Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology. 2012; 266(3):936-44. DOI: 10.1148/radiol.12112516. View

Fujimoto D, Yomota M, Sekine A, Morita M, Morimoto T, Hosomi Y . Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. Lung Cancer. 2019; 134:274-278. DOI: 10.1016/j.lungcan.2019.06.001. View

Ogura T, Takigawa N, Tomii K, Kishi K, Inoue Y, Ichihara E . Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respir Investig. 2019; 57(6):512-533. DOI: 10.1016/j.resinv.2019.06.001. View

Fujimoto D, Morimoto T, Ito J, Sato Y, Ito M, Teraoka S . A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer. 2017; 111:1-5. DOI: 10.1016/j.lungcan.2017.06.008. View

10.

Raghu G, Nyberg F, MORGAN G . The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004; 91 Suppl 2:S3-10. PMC: 2750810. DOI: 10.1038/sj.bjc.6602061. View

11.

Demopoulos K, Arvanitis D, Vassilakis D, Siafakas N, Spandidos D . MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med. 2002; 6(2):215-22. PMC: 6740283. DOI: 10.1111/j.1582-4934.2002.tb00188.x. View

12.

Khunger M, Rakshit S, Pasupuleti V, Hernandez A, Mazzone P, Stevenson J . Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017; 152(2):271-281. DOI: 10.1016/j.chest.2017.04.177. View

13.

Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y . The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011; 6(7):1242-6. DOI: 10.1097/JTO.0b013e318216ee6b. View

14.

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M . All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015; 53(5):232-41. DOI: 10.1016/j.resinv.2015.06.001. View

15.

Enomoto Y, Inui N, Kato T, Baba T, Karayama M, Nakamura Y . Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer. 2016; 96:63-7. DOI: 10.1016/j.lungcan.2016.03.017. View